5 recruiting, 1 active not recruiting, 1 not yet recruiting, 1 terminated. 8 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Recruiting 5, Active not recruiting 1, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Transurethral Resection of Bladder: new trials by email Literature Review of Transurethral Resection of Bladder trials Research Report on Transurethral Resection of Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer Alpha1H, Transurethral Resection of Bladder Tumor (TURBT), Intravesical Chemotherapy - Urinary Bladder Neoplasms, Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 3 | Recruiting | Hamlet Pharma AB | 194 | 2026-09-17 | 2026-09-21 |
| Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer Disitamab Vedotin (RC48), Toripalimab, Transurethral Resection of Bladder Tumor - Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer | Phase 2 / Phase 3 | Not yet recruiting | Tianjin Medical University Second Hospital | 114 | 2026-08-01 | 2026-08-10 |
| Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer multiparametric magnetic resonance imaging (mpMRI) of the bladder, Transurethral resection of bladder tumour (TURBt), Circulating tumour DNA levels assessment - Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Requiring Cystectomy | Phase 3 | Recruiting | University of Rome Tor Vergata | 92 | 2025-08-15 | 2025-07-24 |
| NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment Active Surveillance, Control arm - Definitive bladder treatment - Muscle-Invasive Bladder Carcinoma | Phase 2 / Phase 3 | Recruiting | Peter Black | 688 | 2025-07-28 | 2025-07-30 |
| Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy BCG Solution, Biopsy of Bladder, Cystoscopy - Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8 | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 330 | 2025-07-17 | 2026-10-02 |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Ganglioneuroblastoma, Nodular, Neuroblastoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 478 | 2024-04-19 | 2026-10-30 |
| Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer Atezolizumab, Biopsy of Bladder, Cisplatin - Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 475 | 2019-06-03 | 2026-08-28 |
| Neoadjuvant Treatment in Resectable Pancreatic Cancer External Beam Radiation, Gemcitabine neoadjuvant, Surgery - Pancreatic Cancer | Phase 3 | Terminated | Universitätsklinikum Hamburg-Eppendorf | 32 | 2014-02-01 | 2018-05-11 |
Urinary Bladder Neoplasms (6) · Non-Muscle Invasive Bladder Neoplasms (2) · Ganglioneuroblastoma (1) · Neoplasms (1) · Neuroblastoma (1) · Pancreatic Neoplasms (1)
National Cancer Institute (NCI) (2) · Alliance for Clinical Trials in Oncology (1) · Hamlet Pharma AB (1) · Peter Black (1) · Tianjin Medical University Second Hospital (1) · University of Rome Tor Vergata (1) · Universitätsklinikum Hamburg-Eppendorf (1)
United States (3) · Canada (2) · Australia (1) · China (1) · Czechia (1) · Germany (1) · Italy (1) · New Zealand (1) · Puerto Rico (1)
Eugene Pietzak, MD (1) · Jakob R Izbicki, MD, FACS (1) · Parminder Singh (1) · Peter Black, MD (1) · Sara M Federico (1) · Simone Albisinni, MD, Phd, FEBU (1)
PMID 24906700, PMID 42567733, PMID 42821609
U10CA180886 (1), U10CA180888 (1)